FishCheeks

$RSC, founded by Brian Armstrong...it's in his Bio...why does noone know about this? $researchcoin

[FishCheeks @FishcheeksHQ]

@GeneInvesting Fuck this shit I'm about to sell soon

[FishCheeks @FishcheeksHQ]

@broheim777 Nice

[FishCheeks @FishcheeksHQ]

@GoogleDeepMind Look into Google's/ Alphabet's 10%investment in Prime Medicine $PRME for gene editing

[Alamentarius @alamentarius]

@rtnarch 35,000,000 shares short on PRME. Just sayin...

[Trav @hypergrowth102]

$9 PT upgrade. $PRME

[FishCheeks @FishcheeksHQ]

@braden_tewinkel @williamkahrl @theEdisonZhu @Browpeak Thanks big dog!

[FishCheeks @FishcheeksHQ]

@williamkahrl @braden_tewinkel @theEdisonZhu @Browpeak When's the shareholder meeting

[FishCheeks @FishcheeksHQ]

@techinvestoor So insane...Google investing 10% in $PRME , prime winning arbitration...crickets for the stock

[Tech Investor @techinvestoor]

$ASTS $PRME

The avg person has never heard of $ASTS or $PRME. Yes, you have a group of people that love ASTS & know its technology for D2D is better than Starlink

But the avg person / analyst / fund / VC never even mentions them. Same goes w $PRME.

So yes, we are still early.

[FishCheeks @FishcheeksHQ]

@broheim777 @broheim777 ? A wink or no wink

[FishCheeks @FishcheeksHQ]

@broheim777 Is this about SSPC127

[🐣 @winnicrypto]

$PRME
Have a read
Market cap: USD 560mn
10% of its shares are owned by Google

[Dr J Rould @jrouldz]

$PRME technology sounds too good to be true when you read about it really next generation potential

if I was going to pick just one gene editing company (instead of using the $ARKG index) this would probably be the one

I also appreciate the technical setup here looks like a strong base formed at/under $3

[FishCheeks @FishcheeksHQ]

$PRME

[Sai s Destiny @Sai_s_destiny]

@InvestsZoo4947 @Alex___VA PRME is currently partnering with Benchling AI on assay designs for PM359 BLA, required by FDA alignment.

[FishCheeks @FishcheeksHQ]

@Kalshi Last year $GOOG invested in $PRME at $3.30... so $300 target ?

[FishCheeks @FishcheeksHQ]

@pawcio2009 Many -200 spots lol

[stonkgang @stonkgang]

Well worth a read, the bull case for $PRME is far beyond a 10x.

[Broad Institute @broadinstitute]

OptiPrime, a new AI model from @davidrliu’s lab, helps scientists choose the best pegRNAs to make a desired edit, avoiding slow and costly steps in the lab and streamlining development of gene-editing medicines for rare diseases. https://t.co/RiZVozCVxo

[Yair Einhorn @yaireinhorn]

Today a new and exciting milestone in the intersection of Artificial Intelligence (AI), Machine Learning (ML) and Gene Editing (Prime Editing) - OptiPrime - was introduced by Professor David Liu - from Harvard and the Broad Institute and the co-founder of Beam Tx - $BEAM & Prime Medicine - $PRME. OptiPrime is a mechanism-based machine learning model which was developed specifically for predicting prime editing (PE) efficiencies and suggesting pegRNAs to achieve a user-specified edit. By incorporating existing PE knowledge into its mathematical structure, OptiPrime enables ML training on ~300,000 PE efficiencies and has already enabled the rapid identification of efficient PE strategies across various in vitro and in vivo applications. IMO the key importance of OptiPrime is its ability to expedite the R&D process of cures for genetic diseases by obsoleting months or even years of manual optimization. When it comes to patients who suffer from genetic diseases the time aspect is super critical and by shortening the timeframe of the complicated R&D process OptiPrime provides hope for patients and their families. Godspeed!